<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672448</url>
  </required_header>
  <id_info>
    <org_study_id>CRC2017ZD02</org_study_id>
    <nct_id>NCT03672448</nct_id>
  </id_info>
  <brief_title>The China Longitudinal Aging Study of Cognitive Impairment</brief_title>
  <official_title>Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the
      elderly. The burden of dementia is rising in China, with major medical, social and economic
      impacts. To address this important public health problem, cohort study on elderly cognitive
      disorders should be carry out. The methods of early prevention, early diagnosis and early
      treatment the cognitive disorders in elderly should be found to reduce the burden of the
      social and economic issue due to dementia. At present, the international corresponding
      guidelines have taken gene and brain imaging biomarkers as important indicators of dementia
      pathogenesis research, accurate diagnosis and targeted intervention. Based on the above
      understanding, the study carry out the population cohort study based on accurate diagnosis
      and construct the high standard information and sample bank. The study will establish the
      standard and quality system of geriatric cognitive disorders cohort study (unified standards
      and norms). The study will integrate the standard biological samples stratified acquisition
      function module (homogeneity and precision) of elderly cognitive disorders, and complete the
      construction of biological samples bank and clinical diagnosis and treatment information
      database. The study will apply and develop brain structural and pathological imaging
      technology to support precision diagnosis of senile cognitive disorders. The study will
      evaluate whether peripheral nerve degeneration can predict central nervous system
      degeneration based on the large cohort of elderly study. In addition, The study will make an
      effective supplement the sample bank construction of Shanghai Mental Health Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neuropsychological test battery are used to access the cognitive function of subjects in
      the study. The brain MRI and biochemical examination will be done in the screening period.
      The samples such as plasma, serum, urine and faeces et al. of the subjects will be collected
      in the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence, incidence of neurocognitive disorder</measure>
    <time_frame>5 years</time_frame>
    <description>Prevalence, incidence of neurocognitive disorder such as AD, MCI and other types of dementia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence, incidence of mood disorder</measure>
    <time_frame>5 years</time_frame>
    <description>Prevalence, incidence of mood disorder such as depression, anxiaty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conversion rate</measure>
    <time_frame>5 years</time_frame>
    <description>conversion rate of neurocognitive disorder from Normal Elderly</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Dementia Frontal</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Neurocognitive disorder</arm_group_label>
    <description>Dementias</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Aging</arm_group_label>
    <description>Normal Aging with normal cognitive function</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Naturalistic observation</intervention_name>
    <description>Naturalistic observation</description>
    <arm_group_label>Neurocognitive disorder</arm_group_label>
    <arm_group_label>Normal Aging</arm_group_label>
    <other_name>Normal Aging</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and mRNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        10,000 adult Chinese aged 60 and up who have been living Shanghai will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  registered residents in the community;

          -  â‰¥ 60 years;

          -  without schizophrenia or mental retardation;

          -  be able to communicate and accept physical and cognitive examinations

        Exclusion Criteria:

          -  blind

          -  deaf mute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang Li, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shifu Xiao, M.D., Ph.D.</last_name>
    <phone>00862164387250</phone>
    <phone_ext>73441</phone_ext>
    <email>xiaoshifu@msn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tao Wang, M.D., Ph.D.</last_name>
    <phone>00862164387250</phone>
    <phone_ext>73220</phone_ext>
    <email>wtshhwy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Mental Health Centre</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shifu Xiao, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Tao Wang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dementia</keyword>
  <keyword>depression</keyword>
  <keyword>cohort study</keyword>
  <keyword>sample bank</keyword>
  <keyword>precision diagnosis</keyword>
  <keyword>brain imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

